STX-0712

STX-0712 is a first-in-class Cytotoxicity Targeting Chimera (CyTAC) therapeutic developed by Solu Therapeutics. It is designed to selectively deplete CCR2-positive malignant monocytes, which are key drivers in certain hematological malignancies such as chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). The drug leverages the CyTAC platform, which combines the target-binding specificity of small molecules with the cytotoxic potential of biologics. Mechanistically, STX-0712 binds to the G-protein coupled receptor CCR2—a marker highly expressed on pathogenic monocytes—leading to their targeted elimination while sparing non-malignant cells. Preclinical studies have demonstrated potent and selective depletion of CCR2-positive cells with minimal off-target effects and favorable safety profiles in animal models. As of 2025, it is being evaluated in a Phase 1 clinical trial for patients with advanced or refractory CMML and AML[1][3][4][5][6][7][8][9].